Persistence Market Research has recently released a comprehensive report on the worldwide market for peripheral drug eluting balloons. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.
Key Insights:
Peripheral Drug Eluting Balloons Market Size (2025E): USD 1035.2 Million
Projected Market Value (2032F): USD 1,844.3 Million
Global Market Growth Rate (CAGR 2025 to 2032): 8.6%
Peripheral Drug Eluting Balloons Market - Report Scope:
Peripheral drug eluting balloons (DEBs) are medical devices used to treat peripheral arterial disease (PAD) by delivering anti-restenotic drugs directly to the arterial walls during angioplasty. These devices combine the mechanical benefits of balloon angioplasty with the pharmacological advantages of drug delivery, reducing the incidence of restenosis and eliminating the need for permanent implants. The market serves hospitals, ambulatory surgical centers, and catheterization labs, with applications primarily in the treatment of femoropopliteal and below-the-knee arterial lesions. Market expansion is driven by the increasing global burden of PAD, technological improvements in balloon design and drug coatings, and growing preference for minimally invasive procedures.
Market Growth Drivers:
The global peripheral drug eluting balloons market is propelled by several key factors, including the rising prevalence of peripheral arterial disease due to aging populations and increasing incidences of diabetes and smoking. Advancements in drug coating technologies, such as paclitaxel and sirolimus-based formulations, have significantly improved clinical outcomes, supporting adoption across healthcare settings. The growing demand for minimally invasive and cost-effective alternatives to stenting also boosts market growth. Additionally, favorable reimbursement policies in developed countries and a rise in awareness about PAD and its treatment options further fuel demand for DEBs.
Market Restraints:
Despite strong growth potential, the market faces challenges including stringent regulatory requirements for product approvals, particularly concerning the safety and efficacy of drug coatings. Recent controversies over paclitaxel-coated devices and their long-term safety have raised concerns among clinicians and regulatory bodies, impacting adoption rates. Moreover, high device costs and limited reimbursement in developing regions restrict widespread use. The presence of alternative treatment modalities, such as bare balloons and stents, also poses competitive pressure on the market.
Market Opportunities:
The peripheral drug eluting balloons market presents significant opportunities driven by innovation in coating technologies, expansion into emerging markets, and integration with imaging and navigation technologies for enhanced procedural outcomes. Development of next-generation DEBs with improved drug release profiles and biocompatible materials can capture new demand. Increasing investment in clinical trials and collaboration with research institutions are expected to generate robust data supporting broader clinical use. Moreover, growing healthcare infrastructure in Asia-Pacific and Latin America opens new avenues for market penetration and growth.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the peripheral drug eluting balloons market globally?
Which drug types and anatomical applications are influencing product development and adoption?
How are regulatory frameworks and safety concerns shaping market trends and clinical usage?
Who are the leading companies in the peripheral DEBs market, and what strategies are they employing to strengthen their competitive positioning?
What are the emerging trends and long-term growth prospects across different regions?
Competitive Intelligence and Business Strategy:
These companies are investing in the development of new drug formulations, biodegradable coatings, and balloons with improved deliverability and precision. Collaborations with academic institutions and clinical centers enable real-world validation and product optimization. Expansion into emerging markets through distribution agreements and regulatory approvals plays a critical role in capturing untapped demand and diversifying revenue streams.
Key Companies Profiled:
Abbott Laboratories
Boston Scientific Corporation
Cook Medical Inc.
MicroPort Scientific Corporation (Endovastec(TM))
Medtronic Plc.
Cardinal Health, Inc.
B. Braun Melsungen AG
BIOTRONIK SE & Co. KG
Becton, Dickinson and Company
W. L. Gore & Associates Inc.
Getinge AB
Terumo Corp
Kyoto Medical Planning Co Ltd
iVascular S.L.U
AMG International GmbH
ENDOCOR GmbH
Meril Life Sciences Pvt. Ltd.
Nano Therapeutics Pvt Ltd
Koninklijke Philips N.V.
REVA Medical
Peripheral Drug Eluting Balloons Market Research Segmentation:
Drug Coating:
Paclitaxel Drug Coating
Sirolimus drug Coating
Others
Indication:
Peripheral Arterial Disease
Peripheral Aneurysms
In-Stent Restenosis
Others
Artery Type:
Carotid Arteries
Fem-Pop Arteries
Iliac Arteries
Infrapop Arteries
End User:
Hospitals
Ambulatory Surgical Centers/Outpatients
Cardiac Catheterization Labs
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Peripheral Drug Eluting Balloons Market Snapshot 2025 and 2032